16
Participants
Start Date
September 3, 2025
Primary Completion Date
February 29, 2028
Study Completion Date
February 29, 2028
GNTI-122
GNTI-122 is an investigational cell therapy manufactured from a participant's own blood cells and is intended to help correct an imbalance of certain types of cells found in participants with Type 1 Diabetes.
NOT_YET_RECRUITING
Icahn School of Medicine at Mount Sinai, New York
RECRUITING
University of North Carolina at Chapel Hill, Chapel Hill
RECRUITING
Duke University, Durham
NOT_YET_RECRUITING
University of Florida - Gainesville, Gainesville
NOT_YET_RECRUITING
University of Miami, Diabetes Research Institute, Miami
NOT_YET_RECRUITING
City of Hope Medical Center, Duarte
NOT_YET_RECRUITING
University of California - San Francisco, San Francisco
NOT_YET_RECRUITING
University of California - San Diego, San Diego
NOT_YET_RECRUITING
Joslin Diabetes Center, Boston
Lead Sponsor
GentiBio, Inc
INDUSTRY